$43.91▲ 0.04 (0.09%)
Real-time prices · US MarketsConsensus analyst target of $62.00 is 41% above current price.
analyst sentiment is cautious.
Quality
7.7
Health
6
Growth
6
Valuation
8.6
Sentiment
5
Analyst Target
$62.00
▲ +41.2% from current
Price Chart
Latest News
Fundamentals
Trailing P/E
17.8×
price-to-earnings
Forward P/E
12.8×
next 12 months est.
Market Cap
$63.6B
market capitalization
Div Yield
—
dividend yield
Profit Margin
17.5%
net profit margin
Gross Margin
69.2%
revenue minus COGS
ROE
15.3%
return on equity
Beta
0.57
vs S&P 500
52-Week Range
$42 — $106
annual min — max
Frequently Asked Questions
What do analysts say about Boston Scientific Corporation right now?
Boston Scientific Corporation's Q·Score is 6.8/10 (Neutral), reflecting its current fundamentals, analyst data, and valuation metrics. Consensus analyst target of $62.00 is 41% above current price. Key area to monitor: analyst sentiment is cautious. This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for BSX?
The consensus price target for BSX is $62.00, based on ratings from 29 Wall Street analysts. This is 41.2% above the current price of $43.91. Price targets are forward-looking estimates and not guarantees of future performance.
Is BSX overvalued or undervalued?
Boston Scientific Corporation (BSX) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 12.8×. The consensus analyst price target of $62.00 is 41% above the current price.
What is Boston Scientific Corporation's profit margin?
Boston Scientific Corporation has a net profit margin of 17.5%, which is solid for most industries. Its gross margin stands at 69.2%, indicating a high-margin business model.
Is Boston Scientific Corporation's revenue growing?
Boston Scientific Corporation is reporting modest revenue growth of 7.5%. Earnings are also growing at 15.1%, indicating improving profitability.
How much debt does Boston Scientific Corporation have?
Boston Scientific Corporation has a debt-to-equity ratio of 0.50×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.24×, suggesting it should be monitored for near-term liquidity.